- Home
- CAAP vs MRUS Comparison
CAAP vs MRUS Comparison
Compare CAAP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- MRUS
- Stock Information
- Founded
- CAAP 1998
- MRUS 2003
- Country
- CAAP Luxembourg
- MRUS Netherlands
- Employees
- CAAP N/A
- MRUS N/A
- Industry
- CAAP Aerospace
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CAAP Consumer Discretionary
- MRUS Health Care
- Exchange
- CAAP Nasdaq
- MRUS Nasdaq
- Market Cap
- CAAP 3.3B
- MRUS 4.1B
- IPO Year
- CAAP 2018
- MRUS 2016
- Fundamental
- Price
- CAAP $19.27
- MRUS $54.74
- Analyst Decision
- CAAP Strong Buy
- MRUS Strong Buy
- Analyst Count
- CAAP 2
- MRUS 13
- Target Price
- CAAP $24.35
- MRUS $88.54
- AVG Volume (30 Days)
- CAAP 120.7K
- MRUS 706.3K
- Earning Date
- CAAP 08-20-2025
- MRUS 07-31-2025
- Dividend Yield
- CAAP N/A
- MRUS N/A
- EPS Growth
- CAAP N/A
- MRUS N/A
- EPS
- CAAP 1.05
- MRUS N/A
- Revenue
- CAAP $1,858,038,000.00
- MRUS $54,732,000.00
- Revenue This Year
- CAAP N/A
- MRUS $68.08
- Revenue Next Year
- CAAP $12.97
- MRUS $0.09
- P/E Ratio
- CAAP $18.35
- MRUS N/A
- Revenue Growth
- CAAP 28.46
- MRUS 42.77
- 52 Week Low
- CAAP $13.97
- MRUS $33.19
- 52 Week High
- CAAP $22.13
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- CAAP 38.12
- MRUS 56.79
- Support Level
- CAAP $19.82
- MRUS $51.78
- Resistance Level
- CAAP $20.70
- MRUS $55.30
- Average True Range (ATR)
- CAAP 0.56
- MRUS 1.63
- MACD
- CAAP -0.05
- MRUS -0.11
- Stochastic Oscillator
- CAAP 3.06
- MRUS 84.09
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.